Literature DB >> 10444255

Enhanced B cell survival in familial macroglobulinaemia is associated with increased expression of Bcl-2.

H M Ogmundsdóttir1, S Sveinsdóttir, A Sigfússon, I Skaftadóttir, J G Jónasson, B A Agnarsson.   

Abstract

A family with three cases of macroglobulinaemia of undetermined significance (MGUS), and one case each of immunoblastic lymphoma, Waldentröm's macroglobulinaemia and multiple myeloma was first described 20 years ago. We have previously identified 10 out of 35 healthy family members tested whose lymphocytes produced abnormally high amounts of immunoglobulins in culture. In the present study lymphocyte subpopulations of these hyper-responders have been further characterized and lymphocyte reactivity and survival in vitro have been studied. No differences were detected in the proportions of resting B lymphocytes (CD19+) co-expressing CD5, CD10, CD11b, or CD38, and the CD4/CD8 ratio of T cells was normal before and after stimulation with pokeweed mitogen (PWM). The initial rate of response in terms of immunoglobulin production was not increased, but immunoglobulin levels continued to rise during the second week of culture whereas the production peaked at 8 days in control cultures. This was associated with significantly greater survival of lymphocytes and at 14 days surviving B cells could only be identified in samples from hyper-responders. A lymph node removed because of tuberculosis from a family member 23 years before the diagnosis of multiple myeloma showed very marked Bcl-2 expression in a B cell follicle. This was not seen in a tuberculous lymph node from an unrelated subject. Stimulated cultures from three hyper-responders tested demonstrated significantly higher retention of Bcl-2 in B cells compared with one family control and six unrelated controls. We conclude that the increased production of immunoglobulins previously observed in this family with an inherited tendency for benign and malignant B cell proliferation is the result of enhanced B cell survival, which is associated with increased expression of Bcl-2 following stimulation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10444255      PMCID: PMC1905328          DOI: 10.1046/j.1365-2249.1999.00971.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  39 in total

Review 1.  Bcl-2 initiates a new category of oncogenes: regulators of cell death.

Authors:  S J Korsmeyer
Journal:  Blood       Date:  1992-08-15       Impact factor: 22.113

2.  Skewed B cell VH family repertoire in Bcl-2-Ig transgenic mice.

Authors:  T M Yeh; S J Korsmeyer; J M Teale
Journal:  Int Immunol       Date:  1991-12       Impact factor: 4.823

3.  bcl-2 proto-oncogene expression during human T cell development. Evidence for biphasic regulation.

Authors:  J Gratiot-Deans; L Ding; L A Turka; G Nuñez
Journal:  J Immunol       Date:  1993-07-01       Impact factor: 5.422

4.  Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation.

Authors:  F Pezzella; A G Tse; J L Cordell; K A Pulford; K C Gatter; D Y Mason
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

5.  Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2.

Authors:  A Strasser; A W Harris; M L Bath; S Cory
Journal:  Nature       Date:  1990-11-22       Impact factor: 49.962

6.  Transitions in CD45 isoform expression indicate continuous differentiation of a monoclonal CD5+ CD11b+ B lineage in Waldenstrom's macroglobulinemia.

Authors:  G S Jensen; E J Andrews; M J Mant; R Vergidis; J A Ledbetter; L M Pilarski
Journal:  Am J Hematol       Date:  1991-05       Impact factor: 10.047

7.  Defective in vitro antibody production in response to pokeweed mitogen and influenza antigen in patients with Hodgkin's disease.

Authors:  A Sigfusson; J W Babbage; R L Souhami
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

8.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18).

Authors:  T J McDonnell; S J Korsmeyer
Journal:  Nature       Date:  1991-01-17       Impact factor: 49.962

9.  Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells.

Authors:  M Pettersson; H Jernberg-Wiklund; L G Larsson; C Sundström; I Givol; Y Tsujimoto; K Nilsson
Journal:  Blood       Date:  1992-01-15       Impact factor: 22.113

10.  bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation.

Authors:  T J McDonnell; N Deane; F M Platt; G Nunez; U Jaeger; J P McKearn; S J Korsmeyer
Journal:  Cell       Date:  1989-04-07       Impact factor: 41.582

View more
  3 in total

1.  Chronic immune stimulation and subsequent Waldenström macroglobulinemia.

Authors:  Jill Koshiol; Gloria Gridley; Eric A Engels; Mary L McMaster; Ola Landgren
Journal:  Arch Intern Med       Date:  2008-09-22

2.  Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

Authors:  Zachary R Hunter; Lian Xu; Guang Yang; Nicholas Tsakmaklis; Josephine M Vos; Xia Liu; Jie Chen; Robert J Manning; Jiaji G Chen; Philip Brodsky; Christopher J Patterson; Joshua Gustine; Toni Dubeau; Jorge J Castillo; Kenneth C Anderson; Nikhil M Munshi; Steven P Treon
Journal:  Blood       Date:  2016-06-14       Impact factor: 22.113

Review 3.  Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models.

Authors:  Siegfried Janz
Journal:  ISRN Hematol       Date:  2013-09-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.